American Journal of Obstetrics & Gynecology
Volume 200, Issue 2 , Pages 175.e1-175.e5, February 2009

Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma

  • Behiye P.C. Goksedef, MD

      Affiliations

    • Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH
    • ,
  • Charles Kunos, MD, PhD

      Affiliations

    • Department of Radiation Oncology, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Jerome L. Belinson, MD

      Affiliations

    • Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH
    • ,
  • Peter G. Rose, MD

      Affiliations

    • Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH
    • Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH
    • Corresponding Author InformationReprints: Peter G. Rose, MD, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology/A81, 9500 Euclid Ave, Cleveland, OH 44195

Received 2 May 2008; received in revised form 14 July 2008; accepted 30 August 2008. published online 17 December 2008.

Objective

The objective of the study was to assess the effectiveness of primary chemoradiation for stage IB2 cervical carcinoma.

Study Design

A retrospective study of patients treated with primary chemoradiation at selected hospitals in Cleveland, OH, from 1992 to 2006 was performed. Patients with regional or distant metastasis on pretreatment imaging were excluded. Patients received pelvic teletherapy with weekly concurrent cisplatin and high- or low-dose-rate brachytherapy.

Results

Forty-nine patients with a median age of 51 years were identified. The majority of patients were white (81.6%) and had squamous cell carcinomas (81.6%) and a median tumor diameter of 5 cm (range, 4.1-10 cm). The median duration of follow-up was 41 months. Progression of disease was observed in 10 (20.4%) patients. The local control rate was 86%. At 36 months, the progression-free survival (PFS) was 79% and the overall survival (OS) was 86%.

Conclusion

Primary chemoradiation has a high clinical response rate, PFS, and OS for women with stage IB2 cervical cancer.

Key words: Cervical carcinoma, chemotherapy, radiotherapy, survival

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Cite this article as: Goksedef BPC, Kunos C, Belinson JL, et al. Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma. Am J Obstet Gynecol 2009;200:175.e1-175.e5.

PII: S0002-9378(08)01024-7

doi:10.1016/j.ajog.2008.08.055

American Journal of Obstetrics & Gynecology
Volume 200, Issue 2 , Pages 175.e1-175.e5, February 2009

Article Tools

* Image Usage & Resolution